In a Bloomberg survey based on the recommendations of 24 brokerage companies, Edwards Lifesciences (EW) was given “buy” ratings by ~71% of analysts. About 25% issued “hold” recommendations, and only one issued a “sell” recommendation on the stock.
The table above lists the 17 brokerage companies that have provided target prices for Edwards Lifesciences for the next 12 months. The consensus 12-month target price is $121.4, which amounts to a ~28.8% return potential, compared to Edwards Lifesciences’ price of $94.2 on October 26, 2016.
According to the latest analysts’ ratings update after EW’s earnings release, Northland Securities and Evercore gave the company a one-year target price of $105, the lowest target price among analysts, implying an ~11.4% return over the next 12 months.
Among the large investment banks, JPMorgan Chase gave Edwards Lifesciences a one-year target price of $135, implying a ~48.5% return potential over the next 12 months.
Morgan Stanley and Canaccord Genuity gave the stock its highest one-year target price of $140, implying a return of ~48.5%.
Peers Medtronic (MDT), Boston Scientific (BSX), and St. Jude Medical (STJ) have average broker target prices of $94.7, $27.9, and $81.5, respectively. These figures imply returns of 16.8%, 26.3%, and 3.6%, respectively, over the next 12 months.
Investors can gain diversified exposure to Edwards Lifesciences by investing in the Vanguard Growth ETF (VUG). VUG has 0.23% of its total holdings in Edwards Lifesciences.